Investigational NMIBC treatment TBC-1002 : LIPAC Oncology said that it has wrapped up a phase 1 clinical trial of TBC-1002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and has now initiated a phase 2 A clinical trial. The US pharma company, which is a subsidiary of California-based TesoRx Pharma, said that the phase […]
Continue reading …
Systems Oncology, which uses big data and AI to discover scientific insights into cancer biology, has secured an undisclosed investment from the Pritzker Family Business Interests advised by The Pritzker Organization (TPO) during the first closing of its Series B round. The new capital will be used for investing in discovery research and pre-clinical development […]
Continue reading …
US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies. Elicio Therapeutics said that it has established an international investor base which includes Clal Biotechnology Industries, Efung Capital, and Livzon Pharmaceutical Group. According to the […]
Continue reading …Varian introduces Ethos therapy – AI-powered cancer care delivery solution
September 16, 2019 No Comment
Ethos therapy Varian : Varian, a cancer care technologies developer, has introduced Ethos therapy, an artificial intelligence (AI)-powered personalized cancer care delivery system in radiation oncology, as per the latest medical device news. Ethos therapy, designed to deliver adaptive treatment in a typical 15-minute timeslot, will target the tumor, reduce dose to healthy tissue and […]
Continue reading …
US medical device company Equashield through Japanese distributor Tosho has entered into an exclusive agreement with IV tube manufacturer PAL Medical to provide Equashield’s Closed System Transfer Devices (CSTDs) to oncology nurses in Japan. Post agreement, Tosho will provide PAL Medical with Equashield’s closed IV connectors to develop safer IV sets for oncology nurses administering […]
Continue reading …BioMed, University of California open cancer research center in San Diego
September 7, 2019 No Comment
The University of California San Diego (UC San Diego) and BioMed Realty have opened the Center for Novel Therapeutics (CNT) – a new cancer research center at the former’s Science Research Park in San Diego, California. The cancer research center in San Diego, which spans 137,500sft, has been developed with an investment of $92 million […]
Continue reading …Valo Therapeutics licenses PeptiENV technology from the University of Helsinki
September 2, 2019 No Comment
Valo Therapeutics (Valo Tx) has licensed proprietary PeptiENV technology from Helsinki University that is designed to facilitate the coating of enveloped viruses with antigens associated with tumour. The Finnish immuno-oncology company, which is a spin-out company from the Finland-based University of Helsinki, is focused on developing tumour antigen-coated oncolytic viruses as therapeutic vaccines. Previously, Valo […]
Continue reading …
Following undesired results from the phase 3 MERU clinical trial, US biopharma company AbbVie has terminated the research and development program of Rovalpituzumab Tesirine (Rova-T), an investigational lung cancer drug. The MERU clinical trial is being closed over futility with the phase 3 study, which was assessing Rova-T as a first-line maintenance therapy for advanced […]
Continue reading …
German pharmaceutical giant Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center are joining forces to form a new virtual research and development center (R&D center) to rapidly advance new cancer treatments, covering various forms of the disease including lung and gastrointestinal cancers. The new virtual R&D center is expected to facilitate the […]
Continue reading …
Inrebic FDA approval : Celgene’s subsidiary Impact Biomedicines, has bagged approval for its oral kinase inhibitor Inrebic (fedratinib) capsules from the US Food and Drug Administration (FDA) for the treatment of certain types of myelofibrosis, a rare bone marrow cancer. Fedratinib FDA approval is for the treatment of adult patients with intermediate-2 or high-risk primary […]
Continue reading …
Business News Today
- Vale to sell stake in Henan Longyu Energy Resources to Yongmei
- Astellas Pharma acquires US biotech company Xyphos Biosciences
- Adelphia Gateway pipeline conversion project approved by FERC
- Al-Zour oil refinery project : COOEC-Fluor JV wraps up module program
- Allergan bags Ubrelvy FDA approval for migraine treatment
- Micro Labs, Mylan secure FDA approval for first generics of Eliquis
- LG Electronics to unveil indoor gardening appliance at CES 2020, Las Vegas
- Arcadis Ost 1 offshore windfarm : MHI Vestas to supply V174-9.5MW turbines
- Elsevier acquires 3D4Medical, an Irish anatomy education company
- North Komsomolskoye project : Equinor, Rosneft sanction stage 1 of Russian oil and gas field development
